WO2002092000A3 - Hbm variants that modulate bone mass and lipid levels - Google Patents

Hbm variants that modulate bone mass and lipid levels Download PDF

Info

Publication number
WO2002092000A3
WO2002092000A3 PCT/US2002/014877 US0214877W WO02092000A3 WO 2002092000 A3 WO2002092000 A3 WO 2002092000A3 US 0214877 W US0214877 W US 0214877W WO 02092000 A3 WO02092000 A3 WO 02092000A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hbm
present
diagnosing
bone mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/014877
Other languages
French (fr)
Other versions
WO2002092000A2 (en
Inventor
Kristina Allen
Anthony Anisowicz
James R Graham
Arturo Morales
Paul J Yaworsky
Wei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Oscient Pharmaceuticals Corp
Original Assignee
Wyeth LLC
Genome Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC, Genome Therapeutics Corp filed Critical Wyeth LLC
Priority to JP2002588919A priority Critical patent/JP2004537289A/en
Priority to BR0209563-7A priority patent/BR0209563A/en
Priority to CA002446821A priority patent/CA2446821A1/en
Priority to AU2002316095A priority patent/AU2002316095A1/en
Priority to US10/477,173 priority patent/US7416849B2/en
Priority to EP02746370A priority patent/EP1483288A4/en
Publication of WO2002092000A2 publication Critical patent/WO2002092000A2/en
Anticipated expiration legal-status Critical
Publication of WO2002092000A3 publication Critical patent/WO2002092000A3/en
Priority to US12/219,294 priority patent/US20090136507A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)

Abstract

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.
PCT/US2002/014877 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels Ceased WO2002092000A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2002588919A JP2004537289A (en) 2001-05-11 2002-05-13 HBM variants that regulate bone mass and lipid levels
BR0209563-7A BR0209563A (en) 2001-05-11 2002-05-13 nucleic acid, polypeptide, vector, cell, antibody, methods of diagnosing a phenotype and a patient as expressing a nucleic acid and of identifying agents that modulate the activity of a nucleic acid and a protein and lrp5, lrp6, or hbm and compounds that modulate the interaction of dkk with the wnt signaling path, composition to modulate bone mass and / or lipid levels in a patient, transgenic animal, embryo and animal model, and, agent
CA002446821A CA2446821A1 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels
AU2002316095A AU2002316095A1 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels
US10/477,173 US7416849B2 (en) 2001-05-11 2002-05-13 HBM variants that modulate bone mass and lipid levels
EP02746370A EP1483288A4 (en) 2001-05-11 2002-05-13 HBM VARIANTS THAT MODULATE THE BONE MASS AND LIPID MIRRORS
US12/219,294 US20090136507A1 (en) 2001-05-11 2008-07-18 HBM variants that modulate bone mass and lipid levels

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29007101P 2001-05-11 2001-05-11
US60/290,071 2001-05-11
US29131101P 2001-05-17 2001-05-17
US60/291,311 2001-05-17
US35305802P 2002-02-01 2002-02-01
US60/353,058 2002-02-01
US36129302P 2002-03-04 2002-03-04
US60/361,293 2002-03-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/219,294 Division US20090136507A1 (en) 2001-05-11 2008-07-18 HBM variants that modulate bone mass and lipid levels

Publications (2)

Publication Number Publication Date
WO2002092000A2 WO2002092000A2 (en) 2002-11-21
WO2002092000A3 true WO2002092000A3 (en) 2004-10-07

Family

ID=27501520

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/014877 Ceased WO2002092000A2 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels
PCT/US2002/014876 Ceased WO2002092764A2 (en) 2001-05-11 2002-05-13 Transgenic animal model of bone mass modulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014876 Ceased WO2002092764A2 (en) 2001-05-11 2002-05-13 Transgenic animal model of bone mass modulation

Country Status (7)

Country Link
US (2) US7416849B2 (en)
EP (2) EP1401269A4 (en)
JP (3) JP2004537289A (en)
AU (2) AU2002308681A1 (en)
BR (2) BR0209563A (en)
CA (2) CA2446821A1 (en)
WO (2) WO2002092000A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
EP1285002B1 (en) * 2000-05-26 2007-07-18 Oscient Pharmaceuticals Corporation Regulating lipid levels via the zmax1 or hbm gene
US7416849B2 (en) * 2001-05-11 2008-08-26 Oscient Pharmaceuticals Corporation HBM variants that modulate bone mass and lipid levels
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
EP1395285A4 (en) * 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING INDUCED DKK INTERACTIONS
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2006517109A (en) 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド Amphiregulin antibodies and their use to treat cancer and psoriasis
FR2856410B1 (en) * 2003-06-20 2007-06-15 Integragen Sa METHODS OF PREPARING GENETIC CHIPS AND USES
EP1692167A2 (en) * 2003-11-24 2006-08-23 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
CA2562833A1 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP2412826B1 (en) * 2004-05-07 2014-01-08 Celera Corporation Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof
EP1774017B1 (en) 2004-07-26 2013-05-15 Pfenex Inc. Process for improved protein expression by strain engineering
CA2574881C (en) * 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
FI3345607T3 (en) 2006-12-29 2022-11-30 Methods of altering bone growth by administration of a SOST or WISE antagonist or antagonist
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101951954A (en) 2007-11-02 2011-01-19 诺瓦提斯公司 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP2975411A1 (en) * 2008-06-03 2016-01-20 Universite De Liege Biomarker for osteoarthritis and use thereof
BR112012020257A8 (en) 2010-02-11 2018-02-14 Recombinetics Inc methods and apparatus for producing transgenic artiodactyls
BR112012022044A2 (en) 2010-03-24 2020-08-25 Genentech Inc ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''.
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201291181A1 (en) 2010-05-06 2013-05-30 Новартис Аг COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC POLYVALENT ANTIBODIES AGAINST PROTEIN RELATED TO LOW DENSITY 6 LIPOPROTEIN RECEPTOR (LRP6)
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
KR20140091031A (en) 2011-11-04 2014-07-18 노파르티스 아게 Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
MX2014015204A (en) * 2012-06-12 2015-08-07 Genentech Inc Methods and compositions for generating conditional knock-out alleles.
US8959241B2 (en) * 2012-07-23 2015-02-17 Adobe Systems Incorporated Method and apparatus for performing server-side splicing for live streaming media
EP3068440B1 (en) 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
AU2014363988B2 (en) 2013-12-09 2020-06-11 Baylor College Of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
TW201710503A (en) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 Novel polynucleotides, vectors, pharmaceutical compositions, and uses thereof
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
EP0988379B1 (en) 1997-04-15 2007-04-11 The Wellcome Trust Limited as Trustee to the Wellcome Trust Ldl-receptor
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
BE1011331A6 (en) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Associated polypeptide peroxisome, nucleotide sequence encoding said polypeptide and their use in diagnosis and / or treatment of lung disease or injury.
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
AU4023200A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
CN1454256A (en) * 2000-04-05 2003-11-05 基因组治疗公司 High bone mass gene at 11q13.3
EP1285002B1 (en) 2000-05-26 2007-07-18 Oscient Pharmaceuticals Corporation Regulating lipid levels via the zmax1 or hbm gene
AU2001288214A1 (en) * 2000-06-21 2002-01-02 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
EP1313753A4 (en) 2000-08-18 2004-09-15 Proskelia REGULATOR GENES AND USEABLE SYSTEM FOR THE DIAGNOSIS AND THERAPY OF THE OSTEOPOROSIS
US7416849B2 (en) 2001-05-11 2008-08-26 Oscient Pharmaceuticals Corporation HBM variants that modulate bone mass and lipid levels
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
DE102007020878B4 (en) 2007-05-04 2020-06-18 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Procedure for testing flow noise

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BABIJ P. ET AL: "High bone mass in mice expressing a mutant LRP5 gene", J. BONE MIN. RES., vol. 18, no. 6, 2003, pages 960 - 974, XP002991980 *
BOYDEN L.M. ET AL: "High bone density due to a mutation in LDL-receptor-related protein 5", NEW ENGL. J. MED., vol. 346, no. 20, 16 May 2002 (2002-05-16), pages 1513 - 1521, XP002979590 *
GONG Y. ET AL: "LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development", CELL, vol. 107, 16 November 2001 (2001-11-16), pages 513 - 523, XP002952910 *
JOHNSON M.L. ET AL: "Linkage of a gene causing high bone mass to human shromosome 11 (11q12-13)", AM. J. HUM. GENET., vol. 60, 1997, pages 1326 - 1332, XP000992645 *
LITTLE R.D. ET AL: "A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait", AM. J. HUM. GENET, vol. 70, 2002, pages 11 - 19, XP002287932 *
MAGOORI K. ET AL: "Severe hypercholesterolemia, impaired fat tolerance and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E", E.J. BIOL. CHEM., vol. 278, no. 13, 28 March 2003 (2003-03-28), pages 11331 - 11336, XP002979549 *
MIZUGUCHI T. ET AL: "LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral desity", J. HUM. GENET., vol. 49, 2004, pages 80 - 86, XP002979551 *
See also references of EP1483288A2 *
VAN WESENBEECK L. ET AL: "Six novel missense mutations in the LDL-receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density", AM. J. HUM. GENET., vol. 72, 2003, pages 763 - 771, XP002979550 *

Also Published As

Publication number Publication date
WO2002092764A2 (en) 2002-11-21
WO2002092000A2 (en) 2002-11-21
BR0209563A (en) 2004-12-07
EP1401269A4 (en) 2005-09-28
JP2004537289A (en) 2004-12-16
CA2446821A1 (en) 2002-11-21
AU2002308681A1 (en) 2002-11-25
US20090136507A1 (en) 2009-05-28
US7416849B2 (en) 2008-08-26
EP1483288A2 (en) 2004-12-08
AU2002316095A1 (en) 2002-11-25
JP2011004744A (en) 2011-01-13
EP1483288A4 (en) 2005-09-21
JP2005511002A (en) 2005-04-28
WO2002092764A3 (en) 2003-12-24
BR0209564A (en) 2004-10-26
CA2446859A1 (en) 2002-11-21
US20050070699A1 (en) 2005-03-31
EP1401269A2 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
MXPA03010077A (en) Transgenic animal model of bone mass modulation.
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
TR199801794T2 (en) How long has it been?
ATE364696T1 (en) ABC1 POLYPEPTIDES AND METHODS AND REAGENTS FOR MODULATING CHOLESTEROL CONTENT
WO2001073060A3 (en) 18221, dual specificity phosphatase and uses thereof
ATE352561T1 (en) PGC-1, A NOVEL PPAR-GAMMA COACTIVATOR FROM BROWN ATI TISSUE
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002008273A3 (en) 47508, a novel human histone deacetylase family member and uses thereof
MXPA04004561A (en) A human matrix metalloproteinase and uses therefor.
MXPA02009791A (en) THE HIGH BONE MASS GENE OF 11q13.3.
WO2002070657A3 (en) 93870, a human g-protein coupled receptor and uses therefor
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
EP1281758A3 (en) Four human zinc-finger-containing proteins : MDZ3, MDZ4, MDZ7 and MDZ12
DE60142356D1 (en) 18480 HUMAN PROTEIN KINASEMOLEKÜLE AND ITS USES
DE60138952D1 (en) 16836, A MEMBER OF THE HUMAN PHOSPHOLIPASE C FAMILY AND ITS USES
ZA200207883B (en) The High Bone Mass Gene of 11Q13.3.
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2003057827A3 (en) Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
GB2398785A (en) Human RAS interacting protein
WO2002026958A3 (en) Human neprilysin protease
WO2001066764A3 (en) 16835, a human phospholipase c and uses thereof
EP1243660A3 (en) Human udp-Galnac:polypeptide n-acetylgalatosaminyltransferase 10
EP1262488A3 (en) Human LCCL-domain containing protein
WO2005033293A3 (en) Hypoxia - responsive human cngh-0002 genes and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2446821

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002588919

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002746370

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10477173

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002746370

Country of ref document: EP